TrustRadius: an HG Insights company

Kensho vs. Neurula Scribe

Save this comparison

Save this comparison

Add Product

Recommended Comparisons

    Overview
    ProductRatingMost Used ByProduct SummaryStarting Price

    Kensho

    Score3 out of 10
    N/AKensho solutions discover, extract, link and enrich unstructured data, creating value for users at all levels and roles in an organization. Whether for using Kensho’s solutions on an existing data set or to leverage the breadth, depth and accuracy of S&P Global’s sources, Kensho unlocks insights in hard-to-get-to data, to make it accessible, insightful, relevant and, ultimately, transformative.N/A

    Neurula Scribe

    N/AN/ANeurula Scribe (also called nScribe) is an ambient AI medical scribe from Neurula Technologies, an Abu Dhabi healthcare technology company. It is delivered as a Google Chrome extension and works on top of any web-based EMR, with no API integration or IT project required. Installation takes about five minutes per laptop. During a consultation, the clinician starts recording from the extension. Neurula Scribe transcribes the conversation in real time with automatic…N/A
    Pricing
    KenshoNeurula Scribe
    Editions & Modules
    No answers on this topic
    No answers on this topic
    Offerings
    Pricing Offerings
    KenshoNeurula Scribe
    Free Trial
    NoNo
    Free/Freemium Version
    NoNo
    Premium Consulting/Integration Services
    NoNo
    Entry-level Setup FeeNo setup feeNo setup fee
    Additional Details—Neurula Scribe pricing is quote-based and is not published. A pilot is available on request. Setup takes about five minutes per laptop and requires no server installation or EMR integration.
    More Pricing Information
    Best Alternatives
    KenshoNeurula Scribe
    Small Businesses
    TensorFlow
    Score7.6 out of 10
    No answers on this topic
    Medium-sized Companies
    TensorFlow
    Score7.6 out of 10
    No answers on this topic
    Enterprises
    TensorFlow
    Score7.6 out of 10
    No answers on this topic
    All AlternativesView all alternativesView all alternatives